A Phase I/II Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and feasibility of TC-510 in combination with cyclophosphamide and Fludarabine in patients with solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05451849
Study ID: TCR2-21-01
Trial Phase: Phase I/II
Trial Sponsor: TCR2 Therapeutics
Therapies Used in This Trial: Cyclophosphamide, Fludarabine, TC-510